IPO - Silo Pharma, Inc.

Form Type: 424B4

Filing Date: 2025-05-16

Corporate Action: Ipo

Type: New

Accession Number: 000121390025044625

Filing Summary: Silo Pharma, Inc. is conducting an initial public offering, offering 2,723,336 shares of common stock along with warrants. Each common share is sold with a series A-1 and series A-2 warrant, all priced at $0.60 per share. The offering includes pre-funded and placement agent warrants, totaling the ability to issue up to 7,562,678 shares upon exercise of all warrant classes. The placement agent, H.C. Wainwright & Co., will facilitate sale arrangements but is not guaranteeing specific sale amounts. A sale success hinges on market conditions without a minimum offering requirement, implying potential risks if fewer securities are sold. The expected delivery date for the shares and warrants is around May 16, 2025. The company emphasizes a developmental focus on therapeutics addressing conditions such as PTSD, fibromyalgia, and CNS diseases, with many innovative drug formulations in pipeline discussions, partnerships, and further market potential. Silo's current basis for pricing these offerings integrates various financial and operational metrics while navigating a risk-laden environment for biotech initiatives. The document outlines both the offering details and the company's developmental focus across multiple product candidates.

Form Type: 8-K

Filing Date: 2025-05-16

Corporate Action: Ipo

Type: New

Accession Number: 000121390025044913

Filing Summary: On May 16, 2025, Silo Pharma, Inc. completed a public offering consisting of 2,723,336 common shares, 610,002 prefunded warrants, 3,333,338 Series A-1 warrants, and 3,333,338 Series A-2 warrants. The offering price for each common share and the accompanying Series A-1 and A-2 warrants was $0.60, while the prefunded warrants were priced at $0.5999. The company netted approximately $1.56 million after deducting expenses and plans to use the proceeds for working capital and general corporate purposes. The offering was facilitated by H.C. Wainwright & Co., which received a fee of 7.5% of gross proceeds along with additional compensation. The company is currently under a lock-up agreement that restricts the issuance of certain securities for a specific period. The filing also includes press releases that were issued on May 15 and May 16 announcing the pricing and closing of the offering, respectively.

Form Type: S-1/A

Filing Date: 2025-05-09

Corporate Action: Ipo

Type: Update

Accession Number: 000121390025041563

Filing Summary: Silo Pharma, Inc. is filing an amended S-1 registration statement to register the offering of up to 6,024,096 shares of common stock and 18,524,095 underlying common stock purchase warrants, series A-1 and A-2 warrants, and pre-funded warrants. The offering's assumed public price is $0.83 per share, corresponding to the recent closing price. The registration enables the issuance of the common stock and related securities to potential investors, with a specific emphasis on buyers potentially exceeding 4.99% ownership who can choose to purchase pre-funded warrants instead. The company has engaged H.C. Wainwright & Co., LLC as its placement agent to facilitate this offering. The filing also outlines the risk factors and highlights the developmental stage of Silo Pharma, which focuses on novel therapeutics in biopharmaceuticals for issues like PTSD, anxiety, and chronic pain. The offering's completion is anticipated around May 31, 2025, and investors are cautioned about the high risks associated with the securities. Key details surrounding the regulatory compliance and projections related to the mentioned therapeutics and ongoing research are discussed, reinforcing the company’s commitment to innovative solutions for unmet medical needs.

Form Type: S-1

Filing Date: 2025-04-25

Corporate Action: Ipo

Type: New

Accession Number: 000121390025035652

Filing Summary: Silo Pharma, Inc. has filed a registration statement for an initial public offering (IPO) under Form S-1. The company is offering up to 4,716,981 shares of common stock, along with series A-1 and A-2 warrants, and pre-funded warrants, aiming to raise capital for its biopharmaceutical development programs. The assumed public offering price is $1.06 per share. Silo Pharma focuses on developing novel therapeutics for conditions such as PTSD, fibromyalgia, and Alzheimer's disease, with products in various stages of development. The company is structurally prepared for market entry with an emphasis on collaboration with academic institutions, and it has established several exclusive license agreements. The offering aims to generate funds to further its research and business objectives. The proposed sale is set to occur post-effectiveness of the registration statement, with a termination date for the offering set for May 15, 2025.

Form Type: DRS

Filing Date: 2025-04-11

Corporate Action: Ipo

Type: New

Accession Number: 000121390025030817

Filing Summary: On April 11, 2025, Silo Pharma, Inc. confidentially submitted a draft registration statement under Form S-1 to the Securities and Exchange Commission (SEC) as part of an initial public offering (IPO). This registration statement is not publicly filed and contains details about the offering of up to [●] shares of common stock, common stock purchase warrants, and pre-funded warrants to purchase shares of common stock. Silo Pharma's primary focus is on developing therapeutic solutions for conditions such as PTSD, fibromyalgia, and other CNS diseases. The company is actively working on drug candidates including SPC-15 for anxiety disorders, SP-26 for chronic pain, SPC-14 for Alzheimer’s disease, and SPU-16 targeted for multiple sclerosis. The prospectus outlines the structure of the offering, including pricing considerations, potential risks, and the absence of minimum offering requirements. The anticipated public offering price and terms will be determined based on market conditions at the time of pricing. This initiative is vital for funding the company’s development projects and is subject to the effectiveness of the SEC's review process.

Form Type: POS AM

Filing Date: 2025-03-28

Corporate Action: Ipo

Type: New

Accession Number: 000101376225004209

Filing Summary: Silo Pharma, Inc. filed a Post-Effective Amendment to Form S-1 Registration Statement under the Securities Act of 1933. This amendment updates the registration to include the financial statements for the year ending December 31, 2024, filed on the same date. It pertains to the resale of 820,911 shares of common stock issuable upon the exercise of outstanding warrants. The July 2024 Investor Warrants allow for the purchase of 763,638 shares at an exercise price of $2.75, while the July 2024 Placement Agent Warrants allow for purchase of 57,273 shares at $3.4375 per share. The Warrants are immediately exercisable for five years. Anticipated gross proceeds from exercising all Warrants could be approximately $2.3 million. The Company received regulatory approval for its common stock, which trades under the symbol 'SILO' on NASDAQ. The prospectus outlines Silo’s focus on developing novel therapeutics, including psychedelic formulations for PTSD and CNS disorders, and describes its ongoing preclinical studies for several different product candidates, including SPC-15 for PTSD and SP-26 for fibromyalgia. This document serves as an important step in the company's efforts to facilitate investments and capitalize on its intellectual property and clinical developments.